|

EGFR/HER2 Dual-Target CAR-NK Cells Clinical Trials

1 actively recruiting trial

Pipeline

Phase 1/2: 1

Top Sponsors

  • Beijing Biotech1

Indications

  • Biomarker-positive EGFR/HER2- Expressing HNSCC1
  • Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma1
  • Cancer1

Other1 trial

EGFR/HER2 Dual-Target CAR-NK Cells for Recurrent or Metastatic HNSCC
Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.